is a metabolic disorder caused by enzymic deficiency of aldolase B, a genetically distinct cytosolic isoenzyme expressed exclusively in liver, kidney, and intestine. The molecular basis of this enzyme defect has been investigated in three affected individuals from a nonconsanguineous kindred, in whom fructose-l-phosphate aldolase activities in liver or intestinal biopsy samples were reduced to 2-6% of mean control values.
A B S T R A C T Hereditary fructose intolerance (HFI)
is a metabolic disorder caused by enzymic deficiency of aldolase B, a genetically distinct cytosolic isoenzyme expressed exclusively in liver, kidney, and intestine. The molecular basis of this enzyme defect has been investigated in three affected individuals from a nonconsanguineous kindred, in whom fructose-l-phosphate aldolase activities in liver or intestinal biopsy samples were reduced to 2-6% of mean control values.
To identify a putative enzyme mutant in tissue extracts, aldolase B was purified from human liver by affinity chromatography and monospecific antibodies were prepared from antiserum raised in sheep. Immunodiffusion gels showed a single precipitin line common to pure enzyme and extracts of normal liver and intestine, but no reaction with extracts of brain, muscle, or HFI liver. However, weak positive staining for aldolase in hepatocyte and enterocyte cytosol was demonstrated by indirect immunofluorescence of HFI tissues. This was abolished by pretreatment with pure enzyme protein. Accordingly, a specific radioimmunoassay (detection limit 7.5 ng) was established to quantify immunoreactive aldolase B in human biopsy specimens. Extracts of tissue from affected patients gave 10-25% immunoreactive enzyme in control samples; immunoreactive aldolase in intestinal extracts from four heterozygotes was reduced (to 55%) when compared with seven samples from normal control Received for publication 22 July 1982 and in revised form 17 March 1983. subjects (P < 0.05). In extracts of HFI tissues, there was a sevenfold reduction in apparent absolute specific activity (1.02 vs. 8.82 U/mg) of immunoreactive fructose-l-phosphate aldolase B, but the apparent specific activity in heterozygotes (7.71 U/mg) was only slightly impaired. Displacement radioimmunotitration of aldolase B in liver supernatants showed a significant (P < 0.005) decrease in antibody avidity for immunoreactive protein in HFI tissue when compared with the pure enzyme or extract of normal control liver.
Immunoaffinity chromatography on antialdolase BSepharose facilitated isolation and purification of enzyme from liver biopsy specimens. Active aldolase in normal liver, with substrate activity ratios and Michaelis constants identical to biochemically purified human enzyme, could be recovered from antibody columns. Chromatography on monospecific Fab' antialdolase B enabled pure enzyme protein to be retrieved quantitatively from normal control and HFI liver: direct chemical assay showed 1.88 and 1.15 mg aldolase protein/g of tissue, respectively. This confirmed that the catalytic properties of the HFI aldolase were profoundly impaired with specific activities of fructose-l-phosphate cleavage of 7.21 and 0.07 U/mg, respectively. Radioimmunoassay gave estimates of 7.66 and 1.18 U/mg, respectively. Sodium dodecyl sulfate-polyacrylamide electrophoresis indicated that immunopurified aldolase from HFI liver possessed a single subunit size similar to material from control liver extracts: Mr 39,100 vs. 37,900±700 (SD) D, respectively. Electrofocusing under denaturing conditions of aldolase isolated in parallel from control and HFI liver revealed the same complement of subunits and, despite qualitative differences in distribution of bands during degradation, no additional charged species.
INTRODUCTION
Hereditary fructose intolerance (HFI)' is an inborn error of carbohydrate metabolism characterized by vomiting, abdominal pain, and hypoglycemic symptoms, which follow ingestion of fructose and related sugars (1, 2) . These and other manifestations of the disorder are related to an enzymic deficiency of liver aldolase or aldolase B (3), which is transmitted by an autosomal recessive gene (4) .
Aldolase B (ketose-l-phosphate-aldehyde lyase, EC 4.1.2.7) is chemically and genetically distinct from the A and C isoenzymes and, unlike them, has a powerful catalytic action against D-fructose-l-phosphate (F1P). The enzyme is expressed almost exclusively in liver, kidney, and intestinal mucosa; in HFI, it is these organs that suffer functional impairment and metabolic derangement during challenge with fructose or its cogeners. Under such circumstances, sequestration of phosphate-bond energy in the form of fructose ester generates an intracellular milieu that leads to profound inhibition of both glycogenolysis and gluconeogenesis. Other important sequelae include hypophosphatemia, hyperuricemia and lactic acidosis (5).
It appears that despite the profound deficiency of aldolase B in viscera affected by HFI, sufficient activity for preservation of glycolytic and some glucogenic fluxes in the absence of fructose challenge can be maintained by the A and C isoenzymes. These isoenzymes have preferential activity against aldose diphosphates and possess activity ratios of between 10 and 100:1 for D-fructose-1,6-diphosphate (FDP) and FIP cleavage, respectively. Aldolase A is ubiquitous, but is characteristically expressed in striated muscle; isoenzyme C is expressed mainly in nervous tissue. Aldolases A and C have a low affinity for F1P, as well as low maximum activities; the low substrate affinity is reflected in a high Km for FlP cleavage. Although the three tetrameric isoenzymes are immunochemically distinct, certain hybrid forms have been demonstrated in tissues (6) . In general the presence of aldolase isoenzyme A and C in tissue samples is thus indicated by FDP/F1P substrate activities significantly greater than unity as well as high Km for cleavage of F1P.
Although the pathways of metabolic disturbance that occur in HFI are generally understood, the primary molecular basis of the aldolase defect is obscure. The existence of a functionally modified enzyme protein in the liver of affected individuals has been suggested by the results of kinetic studies. FlP aldolase is usually reduced to below 5% of control activities and this residual enzyme possesses an increased apparent Km (7). Clearly, however, the presence of the other aldolase isoenzymes may partly account for such residual activity, and more convincing evidence for the existence of a modified aldolase B stems from the use of type-specific antisera raised against the rabbit liver enzyme. Liver 16 and 21 yr have been described (4) . These individuals had experienced typical abdominal and hypoglycemic symptoms after fructose or sucrose ingestion since infancy, and the diagnosis of HFI had been made on the basis of formal sugar loading tests (2) . The diagnosis was confirmed by enzymic analysis of aldolase activities in liver or intestinal biopsy specimens: likewise, four asymptomatic heterozygotes from this kindred were identified as previously described (4) . At the time of biopsy, the affected individuals were adhering to a strict exclusion diet (<2 g/d of fructose or equivalent) and were in good general health. Liver tissue was obtained by surgical biopsy in the proband at the time of cholecystectomy for gallstones. In control subjects, tissue samples were obtained during clinical investigation: intestinal mucosa was obtained by capsule biopsy after an overnight fast (8) (10) .
Analytical sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis (PAGE) was carried out under reducing conditions as described by Laemmli (11) Radioimmunoassay of aldolase B in tissue extracts. Human aldolase B was labeled with 1251 in the presence of lactoperoxidase (18) . After removing free iodine, 100% of the radioactivity was precipitated by addition of ice-cold trichloracetic acid to 10% wt/vol. The enzymic -activity of the tracer (sp act -0.05 uCi/gg) was 70% of the native aldolase and retained an FDP/F1P activity ratio close to unity. Twostage radioimmunoassay for aldolase B was carried out with duplicate samples in a final volume of 1 ml. Aprotinin (The Bayer Co., New York, 120 Kunitz U), sodium azide (0.1% wt/vol), phenyl-methylsulphonyl fluoride (0.1 mM) and EDTA (5 mM) were added at the indicated final concentrations to inhibit microbial growth and nonspecific protease activity. The diluent buffer was 0.1 M Tris HCI, 0.15 M NaCl (pH 8.0) and contained 0.5% wt/vol bovine serum albumin (RIA grade, Sigma Chemical Co.); this diluent was heated before use to 56°C for 45 min to inactivate intrinsic enzyme activities. 50 ng of tracer (-3,000 cpm 1251) were added to polycarbonate tubes containing ovine antibody (1/15,000), nonimmune carrier sheep serum (1/1,000) and aliquots of tissue extracts (0.025-0.2% wt/vol) or appropriate dilutions of native aldolase B at the final concentrations indicated, and were incubated at 4°C for 24 (19) , which employs peptic digestion of immunoprecipitated antibody. Optimal proportions of pure enzyme antigen and serum antibody were determined by immunotitration: aldolase activities were assayed in supernatants after precipitation with antibody. Fab' fragments were prepared by reduction of (Fab')2 antibody in the presence of 10 mM cysteine HCI. Coupling to CNBr-Sepharose 6MB followed the standard procedure. About 2 mg of Fab' protein coupled to 1 ml of gel gave an initial binding capacity in excess of 4 U of aldolase B.
High-speed supernatants of 3% wt/vol liver homogenates prepared in Tris buffer were diluted fourfold in 0.1 M ammonium acetate, pH 8.5. 4 ml were then applied over 30 min at room temperature to 0.35-ml columns of Fab'-Sepharose. The affinity gel was treated with 2 ml 8 M aqueous urea and reequilibrated with buffer before use. Samples were reapplied twice to the affinity columns, which were then washed with 70 column volumes of buffer before elution of specifically bound material. The amount of aldolase bound by the gel was checked by enzymic assay of material passing through the columns. Aldolase protein was eluted with 2 bed volumes of deionized 8 M urea containing 1 mM lysine HCI and 1 mM arginine HCI (pH 8.4), and assayed for protein by the method of Lowry et al. (20) , using pure human enzyme as a standard in the calibration curve. Precipitation with sodium deoxycholate and trichloroacetic acid was used to recover small amounts of protein quantitatively and to remove substances interfering in samples and standards with color development (21) Statistical analysis. The significance of differences between groups was assessed by the Mann-Whitney U test (22) . Linear regression was carried out by the method of least squares and the significance of correlation coefficients and differences between slopes or intercepts determined according to the distribution of t (23) . Sigmoid antibody binding data were linearized by angular transformation (23) .
RESULTS
Clinical and laboratory features of HFI. The three affected individuals presented with typical abdominal symptoms and the diagnosis of HFI was based upon tissue enzyme assay (Table I) Immunofluorescence studies were undertaken to identify aldolase B in specimens of HFI tissues. Cryostat sections of normal control liver showed bright cytosolic immunofluorescence in all parenchymal cells (Fig. 3) , which was abolished by prior treatment of the sections with pure aldolase B. Less intense, but specific cytosolic immunofluorescence was demonstrated in epithelial cells of control intestinal mucosa, where it was exclusive to cells maturing distally along the villi. In HFI liver and intestine, only faint fluorescence in a similar distribution was identified, but its specificity was confirmed in appropriate blocking experiments with pure antigen.
Quantification of aldolase B by radioimmunoassay. A radioimmunoassay was established to quantify aldolase B protein in extracts of liver and intestine and to confirm the tentative identification of an immunoreactive aldolase B indicated by indirect immunofluorescence. The detection limit of the assay was 7.5 ng and the sensitivity (ID50) 125 ng protein, after angular transformation of binding values, the assay was rectilinear beyond 1 Ag aldolase per tube (Fig. 4) .
Dilutions of control liver extracts inhibited binding of tracer in parallel to the calibration curve observed on competition with native enzyme (Fig. 5) . Immunoreactive aldolase in control tissue extracts was linearly correlated with measured enzymic activities of FlP aldolase (r = + 0.83, P < 0.001) and no significant cross-reacting material obtained on extrapolation to zero enzyme activity. No significant cross-reacting material was detected in extracts of muscle or brain tissue.
Concentrations of immunoreactive aldolase B and aldolase activities in different human tissues are set out in Table I . Aldolase deficiency in HFI was associated with the presence of 10-25% of control levels of immunologically detectable enzyme protein and contrasts with the more severe deficiency of enzymic activity. In intestinal biopsy samples obtained from asymptomatic individuals heterozygous for HFI, in- termediate aldolase activities were also attended by significant reductions in tissue concentrations of enzyme protein: in this group immunoreactive aldolase B was decreased to 55% of mean control values. The differential reduction of enzymic activity in HFI compared with immunoreactive aldolase B levels is reflected by striking decreases in the apparent specific activity, suggesting the presence of catalytically attenuated enzyme.
To determine whether the enzymic defect in HFI is due simply to a profound deficiency of wild type aldolase B or, as indicated by radioimmunoassay, is related to the production of structurally modified enzyme protein, formal immunotitration was undertaken. Fig. 5 demonstrates that in contrast to preparations of normal control liver, dilutions of HFI liver extract did not exhibit an avidity for antibody identical to that shown by the native enzyme: at comparable proportions of bound radioligand, the efficiency of competitive displacement by HFI respectively. The purity of these samples was verified by electrophoresis (see below) and allowed estimates of absolute specific activity to be made. In control liver, the specific activity of the bound FDP aldolase was 13.3 U/ In HFI liver, the activity of the aldolase B was calculated to be 0.32 U/mg protein (FDP) and less than 0.07 U/mg protein for FIP substrate. These estimates are in close accord with data for the biochemically purified enzyme and the results of assays set out in Tables I and II ; they support the finding of a recovery of only FDP aldolase activity when material from HFI liver was removed from immunoaffinity columns by salt elution. As shown in Fig. 6 , SDS-PAGE under reducing conditions revealed a single band coincident with pure aldolase B when bound material from control liver supernatants was eluted from the pure antibody-Sepharose columns, (Mr 37,900±700 SD, n = 3). Material obtained identically from HFI liver also showed a band in this region but with a greater apparent molecular size (Mr 39,100, mean of two determinations). Isoelectric focusing in the presence of 8 M urea resolved immunopurified liver aldolase into several major charged species, predominantly in the alkaline region (Fig. 7) . Biochemically purified aldolase, which was used to prepare monospecific Fab' antibody fragments, showed a single major subunit band pI 9.6 and is commensurate with the purification schedule using elution for DEAE-Sephadex at pH 9.1 under conditions of low ionic strength. The subunit band is identified in all preparations of control and HFI liver aldolase, irrespective of the immobilized antibody gel used. Immunopurified liver aldolase showed considerable charge heterogeneity, which was more marked in material purified on columns of immobilized crude immunoglobulin, where the subunit bands were qualitatively and quantitatively identical. Although there were qualitative differences between Fab'-Sepharose immunopurified control and HFI aldolase preparations, with a more dominant appearance of less alkaline subunits at the expense of band pl 9.6 in HFI material, the number of charged species is identical. An increase in the number of cycles of freeze/thawing was associated with greater heterogeneity of the immunopurified material and, as illustrated in the figure, these discrete modifications were more apparent in the aldolase isolated from HFI tissue.
DISCUSSION
We have used immunological methods to explore the molecular nature of aldolase B deficiency in HFI. This approach was demanded in part by the limited availability of suitable material for detailed analysis, since genetic expression of the isoenzyme is restricted to inaccessible viscera whose cells do not proliferate readily in culture. In view of these constraints, selected techniques of high sensitivity were used in a study of the function and structure of aldolase in tissue specimens obtained from individuals with HFI by biopsy. Intestinal aldolase B from three affected patients and four asymptomatic heterozygotes was compared with material from control subjects in terms of cytosol concentration (level of immunoreactive protein) and catalytic function (Km, substrate activity ratio, and apparent absolute specific activity). Structural characterization was additionally undertaken in liver tissue obtained from the affected proband at cholecystectomy: antibody binding affinity by competitive displacement; subunit charge and molecular weight by electrophoresis and electrofocusing enzymically active and immunoabsorbed material in polyacrylamide gels.
The Changes of this kind were not observed in heterozygotes, where the presence of sufficient active wild type aldolase to allow a normal phenotype apparently also masks the attenuated catalytic properties of the coexistent variant enzyme. Such findings are important, in that they strongly suggest that the modified functional activity of HFI aldolase B has a direct genetic origin and is not the primary consequence of I deficiency of an unknown activator or presence of an inhibitor. Moreover, the possibility of a genetic defect of posttranslational processing is rendered unlikely since this would likewise not be expected to show discrete gene dosage effects in heterozygous individuals.
Further support for the existence of an enzyme mutant accrues from structural studies. Immunotitration analysis of HFI liver extract showed clear evidence of reduced affinity of the variant aldolase for antibody-findings that are in keeping with the modified behavior in immunodiffusion gels (where precipitin lines were absent) and attenuated tissue immunofluorescence. In this condition, radioimmunoassay detected only 10-25% of control levels of enzyme in several samples of HFI tissues and reduced levels in heterozygotes: an observation that suggests, in studies of a nonconsanguineous kindred, that mutant aldolase from different genetic sources may possess a common disturbance of antibody recognition. The radioassay data are at variance with direct measurements of aldolase protein by chemical assay in HFI liver; these indicate the normal concentrations of enzyme (-0.1% tissue weight) found in control samples of liver by either method. For this reason, estimates based on radioimmunoassay that show a sevenfold reduction of catalytic power, greatly undervalue the functional impairment of aldolase in HFI.
Aldolase B immunopurified from control liver exhibited an apparent subunit molecular weight in the Laemmli system coincident with the biochemically purified wild type enzyme and virtually identical to that reported for the human liver enzyme under the same conditions (24) . Immunopurified aldolase B from HFI liver exhibited an apparent subunit size that was slightly greater (by -1,000 D) than the wild type. In contrast, isoelectric focusing under dissociating conditions indicated charge heterogeneity of immunopurified aldolase from human liver extracts. The biochemically purified enzyme-which was used in the production of monospecific antibody reagents-possessed a single subunit charge species pl 9.3 at 15WC or 9.6 at 0°C. This is entirely in accord with its known amino-acid composition and behavior on ion-exchange chromatography (13), but not with previous reports in whole-liver extracts (25) (26) (27) , which have apparently shown several charged species with pI values close to neutrality. Although it is possible that tissue aldolase B may form heteromeric tetramers, as do other isoenzymes of aldolase (6, 27) , the catalytic activities of the immunopurified liver aldolase are not consistent with such hybridization. Aldolase B may form multienzyme aggregates (28) that could be recognized in situ by monspecific antibodies-a possibility rendered unlikely by the absence of size heterogeneity in the denatured immunopurified liver enzyme. The possibility that the charge heterogeneity reflects impurities in the antibody may be discounted by the finding of heterogeneity of material eluted from Fab'-Sepharose columns, this antibody having been purified after binding to biochemically purified aldolase. Parallelism in the radioimmunoassay between pure enzyme and normal liver supernatant also attests to the specificity of the antisera.
The presence of several charged species of liver aldolase B is compatible with a posttranslational modification and may reflect glycosylation or a nonenzymic process such as oxidation or deamidation. In this regard, the increased formation of less alkaline species at the expense of subunit pl 9.6 in HFI material appeared to be associated with thawing after prolonged storage of the liver sample. Notwithstanding qualitative differences, the identical number of charged species in HFI and control material indicate that the variant aldolase is not directly linked to a genetically determined charge change: the existence of a mutation giving rise to spontaneous instability cannot, however, be excluded. The most likely explanation for apparent discrepancies in pl determinations of liver aldolase B in other reports is failure to achieve equilibrium during focusing-a possibility excluded by comigration of samples in the current study.
Decreased stability of HFI liver aldolase has been demonstrated in heat inactivation experiments (29) and in this laboratory a labile component of fructose diphosphate aldolase was identified similarly in the proband. These studies and others indicating enhanced susceptibility of the variant enzyme to thiol oxidation (30) are in accord with the preferential effects of freeze/thawing on the charge characteristics of the HFI enzyme shown in Fig. 7 . In contrast, gel electrophoresis in the presence of SDS indicated a consistent increase in subunit molecular size while different samples of wild-type enzyme comigrated identically with each other, irrespective of the method of purification (Fig. 6 ). There would thus appear to be no direct relationship between the observed charge heterogeneity and the anomalous molecular size. The isoelectric focusing data of the fresh HFI material showing qualitative and quantitative identity of all subunit forms, including the band pl 9.6 coincident with biochemically purified wild type enzyme, demonstrate that there is no initial charge change of the mutant protein.
It is therefore clear that, although the HFI aldolase may be rendered unstable by mutation, the observed modifications of charge are not primary manifestations of the initial structural mutation itself.
A further question arises as to the nature of the mutation in HFI aldolase. The increase in apparent subunit size of the magnitude detected without a primary change in charge would be unusual if several amino acid substitutions or additions were involved. The findings might indicate the presence of additional neutral residues or the possibility of increased neutral glycosylation at, for instance, a substituted or additional serine or threonine residue. Whatever the genetic process responsible for the production of a modified aldolase in HFI, it would appear to involve a limited alteration in primary enzyme structure; despite this the mutation is accompanied by profound effects on both catalytic activity and antibody recognition. Notwithstanding these effects, the genetic defect responsible for this enzyme variant appears to cause neither gross instability nor deficiency of aldolase B messenger RNA, since immunoreactive protein is readily detected in extracts of tissues that normally express this isoenzyme. A plausible construction, which takes account of the experimental data showing an increased subunit molecular size, immediately suggests a possible mechanism for synthesis of the mutant enzyme. The active site of class I aldolases is located close to the C-terminus and indeed, substrate activity ratios are affected by carboxypeptidase treatment. Clearly, a limited mutation causing misreading of the termination codon would be expected to lead to synthesis of an immunoreactive, but elongated, enzyme protein with modified catalytic properties. The altered functional, immunologic, and structural properties reported here are consistent with this mechanism, particularly in the light of the increased FDP/F1P activity ratio of the mutant enzyme. The functional modifications may thus result from direct effects of mutation in the region of the C-terminus at the catalytic site.
The apparent subtlety of structural variation in the aldolase B is not without precedent: recent structural and functional studies of hypoxanthine-guanine phosphoribosyltransferase, which is variably deficient in Lesch-Nyhan syndrome and certain types of gout, have elegantly detected multiple mutant forms of the enzyme differing structurally with minor changes of molecular weight or charge (31) . The recognition of such diversity, which is clearly a likely consequence of limited, or even point, mutations, raises questions concerning the universality of the present observations of aldolase B deficiency in a single kindred: aldolase B deficiency in other individuals with the HFI phenotype may derive from a range of enzyme mutations.
In summary, we have identified a functional and structural isoenzyme variant in HFI and have provided evidence that the primary molecular defect results from a restricted mutation in the aldolase B gene.
Elucidation of the precise genetic mechanism of such a defect currently would require complete analysis of the expressed enzyme protein phenotype or sequencing at the level of DNA.
